Boston Scientific (BSX)
(Delayed Data from NYSE)
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
by Zacks Equity Research
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
by Zacks Equity Research
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
COO Stock Gains on Q3 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
Cooper Companies' solid segmental results led to an encouraging fiscal third-quarter performance, driving up share prices in after-hours trading.
Neogen (NEOG) Down 1.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark
by Zacks Equity Research
BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.
ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx
by Zacks Equity Research
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
Neogen Suffers From Competitive Pressure, Macroeconomic Woes
by Zacks Equity Research
NEOG faces intense competition, which could affect the marketability and profitability of its products.
PDCO Stock Falls on Q1 Earnings & Sales Miss, Gross Margin Up Y/Y
by Zacks Equity Research
Patterson Companies' first-quarter fiscal 2025 results reflect the negative impact of a cyberattack on its vendor, Change Healthcare.
ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition
by Zacks Equity Research
Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.
Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.
Abbott's Core Businesses Thrive Despite Macroeconomic Issues
by Zacks Equity Research
ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.
Verano Expands U.S. Cannabis Footprint With New Buyouts
by Zacks Equity Research
This deal helps VRNOF foray into the Virginia market ahead of the Adult Use Program launch and will deepen the company's footprint in Arizona cannabis market.
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
by Zacks Equity Research
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
Quest Diagnostics Expands in North America With New Acquisition
by Zacks Equity Research
DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.
Reasons to Retain QIAGEN Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
by Zacks Equity Research
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
HAE vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.
Why Is Boston Scientific (BSX) Up 7.2% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
by Zacks Equity Research
Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Boston Scientific (BSX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
by Zacks Equity Research
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS
by Zacks Equity Research
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.